<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4683">
  <stage>Registered</stage>
  <submitdate>3/11/2014</submitdate>
  <approvaldate>3/11/2014</approvaldate>
  <nctid>NCT02283762</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-001353-16</secondaryid>
    <secondaryid>16277</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Scleroderma, Systemic</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Riociguat (Adempas, BAY63-2521)
Treatment: drugs - Placebo

Experimental: Riociguat - Increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5mg TID and maintenance period of 42 weeks

Placebo Comparator: Placebo - Sham-titration


Treatment: drugs: Riociguat (Adempas, BAY63-2521)
Starting dose 0.5 mg TID, increase by 0.5mg very 2 weeks until highest possible dose of 2.5 mg TID

Treatment: drugs: Placebo
Sham-titration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in mRSS (modified Rodnan skin score)</outcome>
      <timepoint>Baseline to week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>American College of Rheumatology Combined Response Index for Systemic Sclerosis (CRISS) at Week 52</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Assessment Questionnaire disability index (HAQ-DI) domain (separately from the Scleroderma Health Assessment Questionnaire [SHAQ] as part of the calculation of the CRISS algorithm)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient's global assessment</outcome>
      <timepoint>Baseline to 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician's global health assessment on a scaled rating</outcome>
      <timepoint>Baseline to 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in FVC (forced vital capacity) % predicted</outcome>
      <timepoint>Baseline to 52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men or women aged 18 years and older

          -  Systemic sclerosis, as defined by ACR/EULAR (American College of Rheumatology/European
             League Against Rheumatism) 2013 criteria

          -  dcSSc (diffuse cutaneous systemic sclerosis) according to the LeRoy criteria, ie, skin
             fibrosis proximal to the elbows and knees in addition to acral fibrosis

          -  Disease duration of = 18 months (defined as time from the first non-Raynaud's
             phenomenon manifestation)

          -  = 10 and = 22 mRSS (modified Rodnan skin score) units at the screening visit

          -  FVC (forced vital capacity) = 45% of predicted at screening

          -  DLCO (diffusion capacity of the lung for carbon monoxide) = 40% of predicted
             (hemoglobin-corrected) at screening

          -  Negative serum pregnancy test in a woman of childbearing potential at the screening
             visit

          -  Women of childbearing potential must agree to use adequate contraception when sexually
             active. "Adequate contraception" is defined as any combination of at least 2 effective
             methods of birth control, of which at least 1 is a physical barrier (e.g. condom with
             hormonal contraception like implants or combined oral contraceptives, condom with
             intrauterine devices). This applies since signing of the informed consent form until
             30 (+5) days after the last study drug administration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Limited cutaneous SSc (systemic sclerosis) at screening

          -  Major surgery (including joint surgery) within 8 weeks prior to screening

          -  Hepatic insufficiency classified as Child-Pugh C

          -  Patients with isolated AST or ALT &gt;3xULN or bilirubin &gt;2xULN can be included in the
             trial under the condition of additional monitoring during the trial

          -  Estimated glomerular filtration rate (eGFR) &lt; 15 mL/min/1.73m2 (Modification of Diet
             in Renal Disease formula) or on dialysis at the screening visit. Patients entering the
             trial with eGFR 15-29 mL/min/1.73m2 will be undergo additional monitoring of renal
             function

          -  Any prior history of renal crisis

          -  Sitting SBP (systolic blood pressure) &lt; 95 mmHg at the screening visit

          -  Sitting heart rate &lt; 50 beats per minute (BPM) at the screening visit

          -  Left ventricular ejection fraction &lt; 40% prior to screening

          -  Any form of pulmonary hypertension as determined by right heart catheterization

          -  Pulmonary disease with FVC &lt; 45% of predicted or DLCO (hemoglobin-corrected) &lt; 40% of
             predicted at screening

          -  Active state of hemoptysis or pulmonary hemorrhage, including those events managed by
             bronchial artery embolization

          -  Not permitted prior and concomitant medication

          -  Pregnant or breast feeding women

          -  Women of childbearing potential not willing to use adequate contraception and not
             willing to agree to 4-weekly pregnancy testing from Visit 1 (first administration of
             study drug) onwards until 30 (+5) days after last study drug intake.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>15/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>121</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>John Hunter Hospital - New Lambton Heights</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>St Vincent's Hospital - Fitzroy</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles - Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sardegna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Sankt Gallen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Adana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Edirne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Gaziantep</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tyne and Wear</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bath</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate if Riociguat is effective in the treatment of systemic sclerosis</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02283762</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>